Health-related quality of life and cognitive functioning in long-term anaplastic oligodendroglioma and oligoastrocytoma survivors-Reference-Cited by-同舟云学术

Health-related quality of life and cognitive functioning in long-term anaplastic oligodendroglioma and oligoastrocytoma survivors

Published:2013-10-26 Issue:1 Volume:116 Page:161-168
ISSN:0167-594X
Container-title:Journal of Neuro-Oncology
language:en
Short-container-title:J Neurooncol

Author:

Habets Esther J. J.,Taphoorn Martin J. B.,Nederend Sylvie,Klein Martin,Delgadillo Daniel,Hoang-Xuan Khê,Bottomley Andrew,Allgeier Anouk,Seute Tatjana,Gijtenbeek Anja M. M.,de Gans Jan,Enting Roelien H.,Tijssen Cees C.,van den Bent Martin J.,Reijneveld Jaap C.

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Neurology (clinical),Neurology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s11060-013-1278-0.pdf

Reference36 articles.

1. van den Bent MJ, Brandes AA, Taphoorn MJ et al (2013) Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol 31:344–350

2. Cairncross G, Wang M, Shaw E et al (2013) Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9,402. J Clin Oncol 31:337–343

3. Hamlat A, Saikali S, Chaperon J et al (2006) Proposal of a scoring scale as a survival predictor in intracranial oligodendrogliomas. J Neurooncol 79:159–168

4. Sant M, Minicozzi P, Lagorio S, Borge JT, Marcos-Gragera R, Francisci S (2012) Survival of European patients with central nervous system tumors. Int J Cancer 131:173–185

5. Steinbach JP, Blaicher HP, Herrlinger U et al (2006) Surviving glioblastoma for more than 5 years: the patient’s perspective. Neurology 66:239–242

Cited by 84 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PROTON THERAPY FOR ADULT-TYPE DIFFUSE GLIOMA: A SYSTEMATIC REVIEW;Critical Reviews in Oncology/Hematology;2024-09

2. Volumetric Response and Survival of Patients With Bulky IDH-Mutated Grade 3 Glioma Managed With FET-FDG–Guided Integrated Boost IMRT;Clinical Oncology;2024-06

3. State of the Art in Low-Grade Glioma Management: Insights From Isocitrate Dehydrogenase and Beyond;American Society of Clinical Oncology Educational Book;2024-06

4. Cognition and health-related quality of life in long-term survivors of high-grade glioma: an interactive perspective from patient and caregiver;Acta Neurochirurgica;2024-04-03

5. Global health status and fatigue score in isocitrate dehydrogenase-mutant diffuse glioma grades 2 and 3: A longitudinal population-based study from surgery to 12-month follow-up;Neuro-Oncology Practice;2024-03-01